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Bone metastasis from breast and prostate carcinomas is facilitated by activation of bone-resorbing osteoclasts.
Using proteomics approaches, we have identified peroxiredoxin-4 (PRDX4) as a cancer-secreted mediator of
osteoclastogenesis. We now report characterization of L-plastin in the conditioned media (CM) of MDA-MB-231
human breast cancer cells using immunoblotting and mass spectrometry. The osteoclastogenic potential of MDA-
MB-231 CM with siRNA-silenced L-plastin was significantly reduced. L-plastin was detected in cancer-derived
exosomes, and inhibition of exosomal release significantly decreased the osteoclastogenic capacity of MDA-MB-
231 CM. When added to osteoclast precursors primed with RANKL for 2 days, recombinant L-plastin induced
calcium/NFATc1-mediated osteoclastogenesis to the levels similar to continuous treatment with RANKL. Using
shRNA, we generated MDA-MB-231 cells lacking L-plastin, PRDX4, or both and injected these cell populations
intratibially in CD-1 immunodeficient mice. Micro-CT and histomorphometric analysis demonstrated a complete
loss of osteolysis when MDA-MB-231 cells lacking both L-plastin and PRDX4 were injected. A meta-analysis
established an increase in L-plastin and PRDX4 mRNA expression in numerous human cancers, including breast
and prostate carcinomas. This study demonstrates that secreted L-plastin and PRDX4 mediate osteoclast
activation by human breast cancer cells.
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one is the common organ for metastasis from multiple tumors,
cluding breast, prostate, lung, and kidney carcinomas [1].
steoclasts, bone cells that specialize in bone destruction, play a
itical role in establishment of both osteolytic and osteoblastic bone
etastases. Osteoclasts are formed by fusion from monocytic
ecursors of hematopoietic origin. Receptor activator of nuclear
ctor kB (RANK) and its ligand (RANKL) are critical for induction











































































































Translational Oncology Vol. 12, No. 3, 2019 Exosomal Release of L-Plastin by Breast Cancer Cells Tiedemann et al. 463anscription factors NF-kB and AP-1 and protein kinases JNK, ERK,
d p38 [3], leading to expression and activation of the osteoclasto-
nic transcription factor nuclear factor of activated T cells (NFAT)
[4,5]. Inactive hyperphosphorylated NFATc1 is maintained in the
tosol. Calcium signaling, in particular, calcium oscillations
served in osteoclast precursors, stimulates calcineurin, a phospha-
se that dephosphorylates NFATc1 allowing its nuclear translocation
,6]. In addition, signals through co-stimulatory immunoglobulin-
e receptors, such as osteoclast-associated receptor (OSCAR) [7,8]
d triggering receptor expressed in myeloid cells-2 (TREM-2) [8,9],
e critical for stimulation of calcium/NFATc1 signaling and
teoclastogenesis.
Previously, we showed that while RANKL is required during early
ages of osteoclastogenesis, osteoclast formation from late precursors
n be stimulated independent of RANKL by factors produced by
tively proliferating breast [10,11] or prostate [12] cancer cells,
hich activated ERK and calcium/NFATc1 signaling pathways in
teoclast precursors. Since co-stimulatory immunoglobulin-like
ceptors are critical for inducing calcium oscillations and sustained
FATc1 activation [7,9], we examined if the relevant mediators may
immunoprecipitated with IgG. We confirmed that removal of
G-bound factors from media conditioned by MDA-MB-231 breast
rcinoma cells significantly reduced its osteoclastogenic potential and
entified one of the factors as peroxiredoxin-4 (PRDX4) [13]. In this
udy, we report L-plastin as an additional osteoclastogenic factor
leased by breast cancer cells and investigate the cooperative actions
L-plastin and PRDX4 in stimulating osteolysis in an experimental
east cancer bone metastasis model.
L-plastin belongs to a family of actin-binding proteins that consists
three mammalian isoforms sharing 75%-80% homology: I-plastin
lastin-1, fimbrin) expressed in the small intestine, colon, and
dney; L-plastin (plastin-2, LCP1) expressed mainly in hematopoi-
ic cells; and T-plastin (plastin-3, T-fimbrin) expressed in solid
ssues [14,15]. All plastins have been implicated in the cross-linking
actin filaments [15,16]. Physiologically, L-plastin is mainly
pressed in hematopoietic cells [15]; however, many types of
alignant human cells of non-hemapoietic origin express L-plastin
5,17–19]. No extracellular function of L-plastin has been described
date; however, it has been detected in extracellular fluids [20].
In this study, we report identification of L-plastin as a novel soluble
ctor secreted from MDA-MB-231 human breast cancer cells. We
amined the route of L-plastin secretion and explored the
echanism through which it stimulates osteoclastogenesis. An in
vo model of experimental bone metastases was used to assess the
ntribution of L-plastin together with PRDX4 to cancer-induced
teolysis. Finally, the importance of L-plastin and PRDX4 as a
agnostic and prognostic factor for the progression of different types
cancer was validated using publicly available datasets of differential
ne expression in cancer patients.
aterials and Methods
his study was carried out in accordance with the recommendations
the Canadian Council on Animal Care. The protocol was approved
the McGill University Animal Care Committee.
ell Cultures
The MDA-MB-231 breast cancer cell line was provided by Dr.
ter Siegel (McGill University, Montreal) and cultured as previously
scribed [11]. Mouse bone marrow cells were collected as previouslyscribed [21]. Mouse bone marrow cells were collected from 6-week-
d C57BL6/J mice (Charles River). Cells were cultured in 75-cm2
ssue culture flasks (1.5 × 107 cells per flask) with human
combinant macrophage-colony stimulating factor (M-CSF, 25 ng/
l, 300-25, PeproTech Inc.) for 24 hours, and then nonadherent
lls were collected and plated at 5 × 104 cells/cm2 in α-MEM
edium supplemented with 100 U/ml penicillin, 100 μg/ml
reptomycin and 10% fetal bovine serum, M-CSF (50 ng/ml),
d recombinant GST-RANKL (100 ng/ml). Medium was changed
ery other day. On day 5, cell cultures were fixed using 10%
rmalin (23-245-685, Fisher) and stained for tartrate-resistant acid
osphatase (TRAP, Sigma-Aldrich, and 387A-KT). Osteoclasts
ere identified as multinucleated (more than three nuclei) TRAP-
sitive cells and were further characterized by image analysis using
xeLINK Capture SE software (PixeLINK) and Image J. RAW
4.7 cells (TIB-71, American Type Culture Collection) were
ltured in DMEM supplemented with L-glutamine, 1 mM
ruvate, 100 units/ml penicillin, 100 μg/ml streptomycin, and
% FBS. RAW 264.7 cells were plated at 5 × 103 cells/cm2, and
hours later (day 1), recombinant GST-RANKL (50 ng/ml) was
ded. On days 2-3, cells were supplemented with fresh media with
without RANKL (50 ng/ml) or recombinant L-plastin (rP2, 2.5-
μg/ml) +/− a [Ca2+]i chelator BAPTA-acetoxymethyl ester (6-
μM BAPTA, Invitrogen, B6769) for 10 minutes as previously
scribed [22], washed, treated with recombinant L-plastin (rP2,
5-25 μg/ml), cultured for 2 days, fixed, and stained for TRAP. L-
astin was provided by Dr. Jan Gettemans (University of Ghent,
elgium) [23].
ell Culture Reagents
Fetal bovine serum (FBS) was from HyClone (SH 30396-03).
ulbecco's modified Eagle's medium (DMEM), Alpha MEM
MEM, 310-022-CL), Opti-MEM Reduced Serum Medium
ibco, Thermo Fisher, 31985070), sodium pyruvate (600-110-
L), L-glutamine (609-065-EL), penicillin/streptomycin (450-201-
L), and trypsin/ethylenediaminetetraacetic acid (T/E, 325-042-EL)
ere from Wisent Inc. Recombinant human M-CSF (300-25) was
om Peprotech Inc. Recombinant glutathione S-transferase-soluble
ANKL (GST-RANKL) was purified from clones kindly provided by
r. M.F. Manolson (University of Toronto).
reparation of Conditioned Medium
Parental or stably transfected MDA-MB-231 cells were cultured in
-cm2 flasks to 80% confluence and rinsed twice with PBS, 10 ml
serum free medium was added, and cells were cultured for
ditional 24 hours. The conditioned medium was collected and
ntrifuged (100×g, 5 minutes), and then supernatant was filtered
.2-μm filter) and stored (−80°C).
ass Spectrometry
MDA-MB-231 cells were cultured in serum-free medium for
hours. The medium was collected, filtered (0.2-μm filter), and
cubated with 10 μg/ml normal rabbit IgG overnight at 4°C then
ith immobilized Protein A/G-Sepharose overnight at 4°C. After
ntrifugation, the beads were collected and washed twice with 50
M Tris-HCl pH 8.0; 40 mM NaCl; 5 mM EDTA; 1% NP-40
en with 10 mMTris-HCl pH 6.8. Immunoprecipitates were eluted
ith 0.2 M glycine pH 2.5; the samples were boiled in 1× SDS-








































































































464 Exosomal Release of L-Plastin by Breast Cancer Cells Tiedemann et al. Translational Oncology Vol. 12, No. 3, 2019% SDS-PAGE gel. The resulting peptides were identified using
ass spectrometry (Proteomics service platform at the Centre
Innovation Genome Québec).
Samples containing 50 μg of proteins were loaded onto a 10%
S-PAGE followed by staining and destaining. The desired band
as excised from the gel and reduced with DTT, alkylated with
doacetic acid, and digested with trypsin. The lyophilized peptides
ere resolubilized in 0.1% aqueous formic acid/2% acetonitrile and
aded onto a Thermo Acclaim Pepmap (Thermo, 75 μM ID × 2 cm
18 3-μM beads) precolumn and then onto an Acclaim Pepmap
asyspray (Thermo, 75 μM × 15 cm with 2-μM C18 beads)
alytical column separation using a Dionex Ultimate 3000 μHPLC
220 nl/min with a 2%-35% organic gradient (0.1% formic acid in
etonitrile) over 2 hours. Peptides were analyzed using a Thermo
rbitrap Fusion mass spectrometer operating at 120,000 resolutions
WHM in MS1, 15,000 for MS/MS) with HCD sequencing all
ptides with a charge of 2+ or greater. Raw data were converted into
mgf format (Mascot generic format) and searched using Mascot 2.3
ainst human sequences (Swissprot). Database search results were
aded onto Scaffold Q+ Scaffold_4.4.8 (Proteome Sciences) for
ectral counting, statistical treatment, and data visualization.
RNA
MDA-MB-231 cells (150,000 cells/ml) were transfected in
spension (according to manufacturer's suggestion) as follows:
ndling control (untreated cells that underwent all the procedures
ithout treatments), lipofectamine-treated only (Invitrogen), AllStars
gative control siRNA target sequence 5′-CAGTCTTATTCTG-
AATGTAA-3′ (Qiagen, 1027280, 10 nM) or Hs_LCP1_5 target
quence 5′-AACTGCGTTATGAAGAGCTAA-3′ (Qiagen,
04197375, 10 nM). Cells were plated in 6-well plates at 15,000
lls/cm2, and after 6 hours, the medium was changed to culture
edium (DMEM). Twenty-four hours later, a second transfection
as performed in Opti-MEM followed by a medium change after
hours. Forty-eight hours after the first transfection, the cells were
ashed twice with PBS, and serum-free medium was added. Twenty-
ur hours later, CM was collected (0.2-μm filter), aliquoted and
ored (−80°C).
RNA
All lentiviral shRNA vectors were retrieved from the arrayed
ission TRC genome-wide shRNA collections purchased from
gma-Aldrich Corporation [24]. Additional information describing
e shRNA vectors can be found at http://www.sigmaaldrich.com/
e-science/functional-genomics-and-rnai/shrna/library-information.
ml or http://www.broad.mit.edu/genome_bio/trc/rnai.html using
e TRCN number. The following lentiviral shRNA vectors were
ed: shhumanLCP1, TRCN0000056494 and TRCN0000056497
d shhumanPRDX4, TRCN0000064819. Lentiviral supernatants
ere generated as described at http://www.broadinstitute.org/rnai/
blic/resources/protocols. Pooled stable populations were main-
ined under antibiotic selections of 2 μg/ml pyromycin ±7.5 μg/ml
asticidin.
tratibial Injection of Female Nude CD-1 Mice
For in vivo studies, nude CD-1 mice (Charles River) were
aintained under sterile conditions in ventilated cages and racks with
12-hour light/12-hour dark cycle. At 6 weeks of age, female mice
ere randomized into six groups: vehicle (sham) (n = 4); parentalDA-MB-231 cells (n = 5); luciferase shRNA control vector (Luc,
= 5); shRNA for L-plastin (shL, n = 7, shRNA for
roxiredoxin-4 (shP, n = 7); shRNA for L-plastin and PRDX4
hLP, n = 6). MDA-MB-231 cells (1 × 105 cells/mouse) in 20 μl of
BS were inoculated in the left tibia [25]. Mice were euthanized
weeks after the injection.
issue Preparation, μCT, and Histomorphometry
Left tibiae were dissected and immediately fixed in 10% formalin
r 24 hours at 4°C. Bones were transferred to 70% ethanol and kept
4°C until analysis. Micro–computed tomography (μCT) was
rformed using a SkyScan 1272 high-resolution μCT scanner
nnected to a Hamamatsu 20-megapixel camera (Hamamatsu
11871). Images were captured at 61 kV, 142 μA, using a detection
xel of 6 μm and a 0.5-mm aluminum filter. Integration time was set
1400 milliseconds, and 3 images were captured every 0.30°
rough 180° rotation. Reconstruction was performed using SkyScan
econ software and analyzed using SkyScan CT Analysis software.
ibiae metaphyseal trabecular parameters were measured 100 μm
low the growth plate, and a volume of interest of 1.50 mm (250
ides) was analyzed from images acquired at an isotropic resolution of
μm. For histological staining and dynamic histomorphometry,
xed tibiae were decalcified in PBS/EDTA and embedded in paraffin.
ive micrometer-thick cross-sectional sections and tibial longitudinal
ctions were collected using a rotary microtome (Leica Microsystems,
ermany). Sections were stained for H&E and TRAP, and images
ere taken with a Leica DMRB light microscope. TRAP-stained
ages were taken with a Polyvar light microscope at 40× 100 μm
low the growth plate. Osteoclasts were counted and measured using
e osteometric software (Osteometrics Inc.). Embedding, sectioning,
d histomorphometry were performed by the histology platform of
e Bone and Periodontal Research Center of McGill University.
anoparticle Tracking Analysis (NTA)
Extracellular vesicle profiling entailed measurements of size and
mbers of particles secreted from cells cultured in serum-depleted
edium using the NS500 nanoparticle tracking analysis system
anosight, Amesbury, UK) as described previously [26].
olation of Exosomes
Exosomes were purified from MDA-MB-231 conditioned medi-
originating from untreated and shRNA-treated MDA-MB-231
east cancer cells according to the procedure by Vlassov et al. [27].
riefly, MDA-MB-231 breast cancer cells were cultured under
andard conditions. When they reached 80% confluency, the cells
ere washed twice with PBS, and serum-free medium was added to
e culture. After 24 hours, the conditioned medium was collected
d centrifuged at 100×g for 10 minutes to remove cell debris. The
pernatant was further centrifuged at 2500×g for 15 minutes and
en filtered by a 0.22-μm filter (Millipore) before a final
tracentrifugation at 100,000×g for 2 hours. The supernatant was
scarded, and the exosome pellet was washed twice with PBS and
termittent ultracentrifugation at 100,000×g for 2 hours.
est Compounds
Cells were incubated with [Ca2+]i chelator BAPTA-acetoxymethyl
ter (25 μM, Invitrogen, B6769) for 10 minutes as described
eviously [22], washed, and treated with 10 μg/ml of recombinant












































































































Translational Oncology Vol. 12, No. 3, 2019 Exosomal Release of L-Plastin by Breast Cancer Cells Tiedemann et al. 465ft fromDr. Jan Gettemans, Ghent University, Belgium [23]. Before use,
e neutral sphingomyelinase inhibitorGW4869 (used to inhibit exosome
oduction) was resuspended in DMSO (7.5 mM) and aliquoted and
ored at −70°C. Upon use, GW4869 was solubilized in 1/20 volume of
methanesulfonic acid (working solution 10 μM) [28].
rotein Extraction, Immunoblotting, and Immunofluorescence
For CM, 1 ml of CM was TCA-precipitated and applied on a 10%
S-PAGE gel followed by immunoblotting. For cell lysates,
traction was performed in RIPA lysis buffer containing 50 mM
ris, pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 1 mM EDTA,
mg/ml aprotinin, 2 mg/ml leupeptin, 0.1 mM phenylmethylsul-
nyl fluoride, 20 mM sodium fluoride, and 0.5 mM sodium
thovanadate. Samples were centrifuged at 12,000×g for 10 minutes
4°C, supernatant was collected, and protein was measured using a
uant-iT protein assay kit (Invitrogen, Q33211). Ten to 20 μg of
sates were separated on a 10% SDS-PAGE and transferred to a
trocellulose membrane (0.45 μm, 162-0115, Bio-Rad) using
mM sodium borate buffer. The membranes were blocked in
milk for 1 hour at room temperature followed by overnight
cubation at 4°C with primary antibodies: anti–plastin-1 (1:300,
BP1-56555, Novus), anti–L-plastin (1:300, MA5-11921, Thermo
sher), anti–plastin-3 (1:300, T-plastin, A-3, SC-16620B), anti-
lnexin (1:1000, NB100-1965, Novus), anti–α-tubulin (1:5000,
9026, Sigma), anti-CD9 (1:150, ab92726, Abcam), and anti-
SG101 (1:150, ab83, Cedarlane). The blots were washed, incubated
ith horseradish peroxidase–conjugated secondary antibodies
:1500, anti-mouse, 170-5047; 1:1500, anti-rabbit, 170-5046;
io-Rad), and visualized with a chemiluminescence system (Super
nal West Pico; 34,080, Pierce). Immunoblots were quantified using
nsitometry with ImageJ. For immunofluorescence, cells plated on glass
verslips were fixed with 10% formalin, and immunostaining was
rformed as described previously [10] using anti-NFATc-1 (1:100, 7A6,
nta Cruz Biotechnology) and Alexa Fluor 488–conjugated secondary
tibody (Invitrogen, A32723). Nuclei were counterstained with 4′,6-
amidino-2-phenylindole (DAPI, Invitrogen). Five random images per
perimental condition were collected each containing 10-15 precursors.
ells were rated positive for nuclear localization of NFAT if fluorescence
tensity of nuclei exceeded that of the cytoplasm.
ransmission Electron Microscopy (TEM)
Purified exosomes were washed by ultracentrifugation (100,000×g,
minutes, and 4°C) in 0.2 M hydroxyethyl piperazineethanesulfo-
c acid (HEPES) pH 7.25 solution. All supernatant was removed,
d pellet was resuspended in 2.5% glutaraldehyde in 0.1 M HEPES
7.25 solution. Five microliters of fixed exosome solutions were
sorbed on each glow-discharged carbon-coated nickel grid and
lowed to air dry for 5 minutes. Uranyl formate solutions were
epared by dissolving 7.5 μg uranyl formate in 500 μl boiling water
d subsequently adding 1.25 μl 10 N NaOH and vigorous shaking.
lutions were then centrifuged at 21,000×g for 5 minutes to remove
bris, and supernatants were collected and used. The grids were
gatively stained with 5 μl of uranyl formate solution and allowed to
r-dry for 15 minutes. Exosomeswere imaged using a Philips TECNAI
electron transmission microscope. Microscope tension was set to
0 kV, and grid was inserted to the sample holder. After ensuring that
cuum was maintained, the height of the beam was adjusted using the
obbler function. Intensity, focus, and magnification were adjusted
cordingly, and AMT camera was used to capture images.xpression Clones and Recombinant Protein Purification
The ORF expression clones for human Plastin-1 (EX-Z6971-B31)
d Plastin-3 (Ex-S0326-B1) were from Gene Copoeia Inc. and
pressed in DH5α cells according to manufacturer's recommenda-
n. The recombinant plastin-1 and -3 were purified using nickel
agnetic beads for his-tag protein purification (B23601) from
ioTools Inc. Recombinant human L-plastin was a kind gift from Dr.
n Gettemans, Ghent University, Belgium [23]. The GST-tagged L-
astin was purified on a glutathione sepharose 4B column
7075602, GE healthcare).
icrospectrofluorometry
Raw 264.7 cells were plated onto glass-bottom 35-mm dishes
atTek Corp.). RANKL-primed cells were washed twice with
MEM containing 10 mM HEPES and labeled with Fura-2-AM
1221, Invitrogen) at room temperature for 40 minutes. Cells were
ashed twice and imaged using a fluorescence inverted microscope
2000, Nikon), cooled charge-coupled device camera (Hamamatsu)
nnected to the image analysis software (Volocity, Improvision),
hich recorded fluorescence emission at 510 nm, following excitation
340 and 380 nm alternated by a high-speed wavelength switching
vice (Lambda DG-4, Quorum Technologies). Vehicle and 10 μg L-
astin were added to the bath. Changes in [Ca2+]i were measured for
minutes at baseline and after the addition of compounds.
uantitative Real-Time PCR (qPCR)
Total RNA was isolated from primary cultures using the RNeasy
ini kit and QIAshredder columns (Qiagen, 74104 and 79654). For
al-time PCR, 1 μg of total RNA was reverse transcribed using a
NA archive kit (Applied Biosystems, 74322171). Real-time PCR
as performed using 7500 Applied Biosystems instrument using
aqMan probes with the universal PCRMasterMix (Life technologies,
04437) in a total volume of 20 μl. The following probes were used:
aqMan: L-plastin, (LCP1): Hs00158701_m1 and glyceraldehyde
hydrogenase phosphate (GAPDH): Hs03929097_g1.
eta-Analysis of LCP1 and PRDX4 Differential Expression in
uman Cancers
Datasets for LCP1 and PRDX4 mRNA expression (expressed as
anscripts per million; TPM) in normal tissues and tumors were
tracted from The Cancer Genome Atlas (TCGA) database using
CGA Assembler 2 on July 2, 2018 [29], and data were log-
ansformed to establish normality. Differential expression of LCP1
d PRDX4 was determined as the standardized mean difference
MD) between normal tissue and primary cancer sites. To determine
e average differential expression of each gene, the pooled SMD
ross all tumor types was estimated using the meta-analytic toolbox
etaLab in MATLAB R2016b (MathWorks) [30], assuming a
ndom effects model for which the variance of cancer-specific effects
as determined using the DerSimonian-Laird estimator [31]. To
vestigate whether there was an association between the changes in
P1 and PRDX4 expression, data were first partitioned into two
oups in which LCP1 was either up- or downregulated at the
imary cancer site, and the relationship between LCP1 and PRDX4
anges for each subgroup was analyzed by linear regression in
ATLAB. The direction (positive or negative) and strength (R2) of
sociation were reported. Where applicable, 95% confidence intervals
Is) were estimated using critical values from the z-distribution (i.e.,





















































466 Exosomal Release of L-Plastin by Breast Cancer Cells Tiedemann et al. Translational Oncology Vol. 12, No. 3, 2019atistically significant if the 95%CI did not overlap with the null effect
.e., SMD = 0). When specified, pairwise comparisons between
rmal tissue and primary tumor gene expression were conducted
ing two-tailed Student's t test, and P values were reported.
tatistics
Data are presented as means ± standard error of the mean (S.E.)
ith sample size (n) indicating the number of independent
periments, or as means ± standard deviation (S.D.) with sample
ze (n) indicating the number of samples. Differences were assessed





Figure 1. L-plastin is an osteoclastogenic factor secreted from
MDA-MB-231 breast cancer cells. (A) Immunoblotting for I, L, and
T-plastin (IPL, LPL, and TPL) in MDA-MB-231 cell lysates (CL) and
conditioned medium (CM). Equal loading was visualized by
Ponceau staining (lower gels). (B-D) L-plastin was transiently
depleted in MDA-MB-231 cells (MD-231) using siRNA for L-plastin
specific oligos (siLPL) or negative control (siNC). (B) L-plastin
mRNA (top) and protein (bottom) expression in parental (−) and
siLPL cells. (C, D) RAW 264.7 cells were primed with RANKL
(50 ng/ml) for 2 days and then cultured for additional 2 days
without treatment (negative control, NC), with RANKL (50 ng/ml,
PC), or with 10% CM from siNC or siLPL MDA-MB-231. Average
numbers (C) and representative images (D) of osteoclasts (OC)
formed in indicated conditions. Scale bar of 100 μmapplies to both
images. Data are means ± SD, N = 2. (E, F) Protein expressions of
L-plastin in whole cell lysates (E) and CM (F) in human
erythroleukemia cells K562, human embryonic kidney cells 293
(HEK), normal skin fibroblasts (NSF), prostate carcinoma cells
(PC3), human breast carcinoma cells MCF7 and MDA-MB-231
(231), and mouse breast carcinoma cells (4T1) were determined
using immunoblotting. Protein loading was assessed using α-
tubulin for cell lysates (E) and Ponceau stain for CM (F).esults
entification of L-Plastin as a Potential Osteoclast Stimulating
actor Secreted from Breast Cancer Cells
We have previously demonstrated that soluble factors produced by
east [10,11] and prostate [12] cancer cells induce osteoclast
fferentiation and that peroxiredoxin-4 (PRDX4) is one the
ediators of these osteoclastogenic effects [13]. Another protein
entified by mass spectrometry in the osteoclastogenic fraction was
astin (Supplemental Figure 1A). The three plastin isoforms, I-
astin (PLS1), L-plastin (LCP1), and T-plastin (PLS3), are typically
scribed as intracellular proteins. Since plastin isoforms have a high
gree of homology, we first confirmed the specificity of the
tibodies for different isoforms. Antibodies for T- and L-plastins
ere specific, while the I-plastin antibody exhibited high nonspecific
nding at lower molecular weights; antibody against T-plastin
entified a product in both T- and I-plastin lysates; however, the
olecular weight was lower than expected (Supplemental Figure 1B).
ext, we examined the protein levels of plastin isoforms in MDA-
B-231 cell lysates and conditioned media (CM) using immuno-
otting. All plastin isoforms were present in the breast cancer cell
sates; however, only L-plastin was detected extracellularly in the
DA-MB-231 CM (Figure 1A). We dissected the electrophoresis
and between 60 and 70 kDa and analyzed it with mass
ectrometry. With a 95% probability, we identified 13 peptides
at originated from L-plastin and 5 peptides from T-plastin. A
ansient siRNA knockdown of L-plastin in MDA-MB-231 cells
igure 1B) resulted in a decrease in the ability of breast cancer cell to
duce osteoclastogenesis (Figure 1C, D). Similarly, knockdown of L-
astin in mouse breast carcinoma 4T1 cells decreased their ability to
imulate osteoclast formation (Supplemental Figure 2). L-plastin was
und in cell lysates (Figure 1E) and CM (Figure 1F) in the breast
CF7, 4T1, and MDa-MB-231), prostate (PC3), and erythroleu-
mia (K562) cancer cells but not in normal skin fibroblasts (NSF).
f interest, we commonly observed two bands in some cell lysates
d most CM samples, suggesting the possibility of splice variants or
oteolytic products. Thus, we demonstrate that L-plastin is
pressed and secreted by breast cancer cells and is potentially
volved in stimulation of osteoclastogenesis.
xosomal Release of L-Plastin from MDA-MB-231 Cells
Plastins are intracellular proteins; therefore, we next examined the
echanism of their release from MDA-MB-231 cells. Since L-plastin
as previously found in the vesicular compartment [32,33], we
olated the vesicular fraction from MDA-MB-231 CM using
fferential centrifugation. The average vesicular size was 135 nmigure 2A), and their transmission electron microscopy appearance
as circular with a central depression (Figure 2B), consistent with
osomes. Immunoblotting confirmed the presence of two specific


















































Figure 2. Exosomes in MDA-MB-231 conditioned medium contain L-plastin. (A) Exosomes were purified fromMDA-MB-231 CM, and the
distribution of particle sizes was analyzed with Nanosight. (B) Representative transmission electron microscopy image of exosomes
purified from MDA-MB-231 CM. (C) Proteins from purified exosomes collected from 10 ml of MDA-MB-231 CM were immunoblotted
against exosomal markers, CD9 and TSG101, and L-plastin (LPL). (D) Immunoblotting for L-plastin inMDA-MB-231 cell lysate (CL) or in CM
before (+) and after (−) exosome depletion by differential centrifugation. Numbers above the lanes indicate relative density of L-plastin
band compared to Ponceau (lower gels). (E) CM was collected from MDA-MB-231 cells cultured without or with exosome inhibitor
GW4869 (10 μM, 48 hours). RANKL-primed osteoclast precursors were cultured for an additional 2 days without RANKL (negative
control, NC), with RANKL (50 ng/ml, PC), or with 10%CM from untreated or GW4869-treated (white bar) MDA-MB-231. Data are means ±
SEM, N = 3; *P b .05, compared to negative control, #P b .05 compared to no GW4869 treatment, assessed by Student's t test. (F)
Immunoblotting for PRDX4 and exosomal marker TSG101 in MDA-MB-231 cell lysate (CL), in CM before (+) and after (−) exosome
depletion, or in purified exosomes (Exo). Ponceau stain (lower gels) was used as loading control.
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astin was still evident in the conditioned medium after isolation of
osomes by ultracentrifugation (Figure 2D). The treatment of
DA-MB-231 cells with an exosome inhibitor GW4869
gnificantly reduced the osteoclastogenic potency of MDA-MB-
1 CM (Figure 2E). We examined if PRDX4 was also released by
osomes; however, PRDX4was not detected in purified exosomes but
as present inMDA-MB-231 cell lysates and CMboth before and after
pletion of exosomes (Figure 2F). Thus, at least in part, breast cancer
lls deliver L-plastin into the extracellular space through exosomal
lease.
duction of Osteoclast Formation by Recombinant Human L-
lastin Induces
We next examined if L-plastin can directly induce osteoclast
rmation. We primed RAW 264.7 cells with RANKL for 2 days,
ashed the precursors, and cultured them with recombinant human
-plastin for an additional 2 days (Figure 3A). The effect of L-plastin
osteoclast formation was similar to the positive control (cells
ltured with RANKL for 4 days) and resulted in a significant
crease in osteoclast numbers compared to the negative control (cells
ltured with RANKL for 2 days, then without additions for 2 days).
milarly, addition of recombinant T-plastin resulted in a significant
crease in osteoclast number, while in the presence of I-plastin,
crease in osteoclast numbers did not reach statistical significance
igure 3, B-C). Addition of control proteins recombinantly
oduced in bacterial system did not affect osteoclast formationigure 3, B-C). Increase in the number of osteoclasts in recombinant
astin-treated cultures was accommodated with a corresponding
crease in osteoclast size and nucleation (Supplemental Figure 3).
We have previously shown that soluble factors produced by MDA-
B-231 cells stimulate osteoclastogenesis through the calcium-
pendent NFATc1 nuclear translocation [10,11]. We examined if
plastin similarly affects Ca2+/NFATc1 pathway in osteoclast
ecursors (Figure 4). Addition of recombinant L-plastin to the
ANKL-primed osteoclast precursors induced immediate oscillations
[Ca2+]i (Figure 4A), evident in a significant increase in the average
d variability in [Ca2+]i levels (Figure 4B). Moreover, L-plastin
duced a significant increase in the proportion of osteoclast
ecursors exhibiting nuclear localization of NFATc1 (Figure 4C).
hen calcium signaling was prevented using a calcium chelator
APTA-AM, L-plastin–induced NFATc1 nuclear translocation was
gnificantly decreased (Figure 4C), and the effect of L-plastin on
teoclast differentiation was significantly diminished (Figure 4D).
hus, recombinant human L-plastin induced osteoclast formation
om RANKL-primed precursors through stimulation of Ca2+/
FATc1 pathway.
oss of Osteolytic Potential by L-Plastin and PRDX4-Deficient
DA-MB-231 Breast Cancer Cells
We generated MDA-MB-231 cells stably transfected with shRNAs
ainst L-plastin (shL), peroxiredoxin-4 (shP), or the combination of
th L-plastin and peroxiredoxin-4 targeting shRNAs (shLP)






































Figure 3. Recombinant L-plastin induces osteoclast differentiation from RANKL-primed precursors. (A-C) RAW 264.7 cells were primed
with RANKL (50 ng/ml) for 2 days and then cultured for an additional 2 days without RANKL treatment (negative control, NC), with RANKL
(50 ng/ml, positive control, PC), with human recombinant L-plastin (rLPL) at different concentrations (5, 10, or 25 μg/ml) (A), or with
human recombinant I-plastin-1 (rIPL), L-plastin (rLPL), T-plastin (rTPL), or control protein (rCP, an unrelated protein produced by the same
process) (5-10 μg/ml), (B) and average osteoclast numbers were assessed. Data are means ± SEM., N = 3-11 independent experiments,
***P b .001 **P b .01, *P b .05 assessed by ANOVA and compared to NC by post hoc Bonferroni test. (C) Representative images of
TRAP-stained osteoclast cultures formed in indicated conditions; 100-μm scale bar applies to all images.
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parental and empty vector (Luc) MDA-MB-231 cells. L-plastin
pression in cell lysates and CM was reduced in all clones, including
DA-MB-231 cells harboring only the PRDX4-targeting shRNAs
hP). In contrast, PRDX4 expression was reduced only in the MDA-
B-231 clones that harbor PRDX4 targeting shRNAs (shP). These data
ggest that L-plastin expression is downstream of PRDX4.
Next, female CD-1 immunodeficient mice were injected in the left
bia with i) PBS (sham); ii) human MDA-MB-231 cells, naïve or
pty-vector transfected; iii) L-plastin deficient MDA-MB-231 cells
hL); iv) PRDX4 deficient MDA-MB-231 cells (shP); or v) MDA-
B-231 cells deficient for both L-plastin and PRDX4 (shLP), and
ne loss was examined 2 weeks after surgery (Figure 6). We observed
significant difference between mice inoculated with parental or
pty vector-transfected MDA-MB-231 cells and combined these
oups for further analysis as a positive control group. Histological
alysis demonstrated a significant decrease of bone volume per tissue
lume (BV/TV) and a tendency for increase in osteoclast number
r bone perimeter in positive control samples compared to sham
igure 6A-C). In tibias injected with clones harboring shL, shP, andLP targeting shRNAs, BV/TV was not significantly different from
am, while in tibias injected with clones harboring the shLP
RNAs, the BV/TV was also significantly higher than in positive
ntrol group (Figure 6B). No increase in osteoclast numbers
mpared to sham was evident in tibia injected with MDA-MB-231
ones harboring shL, shP, or shLP constructs, and clones deficient in
RDX4 demonstrated significant (shP) or trending (shLP, P = .1)
crease in osteoclast numbers compared to positive control
igure 6C). μCT confirmed that MDA-MB-231 cells deficient in
th L-plastin and PRDX4 (shLP) were unable to induce osteolysis,
hich is evident by higher BV/TV, trabecular number, and bone
ineral density compared to positive control, cancer samples (Figure
-E). These data suggest that L-plastin and PRDX4 are involved in
ediating breast cancer–induced osteolysis in vivo.
ifferential Gene Expression of LCP1 and PRDX4 in Primary
arcinomas
Using datasets from TCGA [29], we examined LCP1 and PRDX4
RNA levels in normal human tissue and primary tumors;





































Figure 4. L-plastin induces [Ca2+]i oscillations and sustained NFATc1 translocation in osteoclast precursors. (A-B) Fura2-loaded RANKL-
primed RAW 264.7 cells were imaged at baseline, 50 μg/ml recombinant L-plastin (rLPL) or same amount of media, vehicle (Veh) was
added to control for mechanical perturbations, and changes in [Ca2+]i were imaged for additional 60-120 seconds. (A) Top: representative
[Ca2+]i recordings (top, 10- second bar indicates time scale) in seven individual cells per experimental condition. Bottom: For each cell,
the average variation in [Ca2+]i, measured as a standard deviation of [Ca
2+]i, levels was determined and presented in ascending order. (B)
Average [Ca2+]i (top) and variation (standard deviations of [Ca
2+]i level, bottom). Data are means ± SEM, N = 33-63 cells/condition, from
four independent experiments, **P b .01, ***P b .001 compared to baseline, assessed by ANOVA and post hoc Bonferroni test. (C)
NFATc1 localization was assessed by immunofluorescence (green); nuclei were stained with DAPI (blue). RAW264.7 cells cultured for
2 days untreated (−) or primed with RANKL (50 ng/ml). The cells were washed and incubated for 2 hours in the fresh medium without
RANKL (2), with RANKL (50 ng/ml, 2+), with L-plastin (rLPL, 10 μg/ml), or with L-plastin (10 μg/ml) following pretreatment with 25 μM
BAPTA-AM (rLPL+BA). Left: representative images, 10-μm scale bar applies to all images. Right: average percentage of cells with nuclear
NFATc1 from total number of cells scored (N50 cells per condition). Data are means ± SEM, N = 2-4 independent experiments, *P b .05
compared to NC, assessed by ANOVA and post hoc Bonferroni test, #P b .05 for compared to rLPL vs. rLPL+BAPTA by Student's t test.
(D) RAW 264.7 cells were cultured untreated or primed with RANKL (50 ng/ml) for 2 days and then cultured for additional 2 days without
treatment, with RANKL (50 ng/ml), or pretreated with 25 μMof BAPTA or its vehicle and treated with L-plastin (rLPL). Average numbers of
osteoclasts formed in indicated conditions (numbers 2 and 5 indicate for how many days cells were exposed to RANKL). Data are means
± SEM, N = 3-6 independent experiments, **P b .01, compared to NC, #P b .05 compared to rLPL by ANOVA.
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pression of LCP1 and PRDX4 in other primary cancer types
igure 7, Table S1). Both LCP1 and PRDX4 were significantly
evated in primary invasive breast carcinoma (BRCA) and primary
ostate adenocarcinoma (PRAD). In addition, LCP1 was signifi-
ntly upregulated or demonstrated tendencies towards an increase in
merous cancer types, including kidney renal clear and papillary cell
rcinomas, as well as glioblastoma multiform; and was significantly
wnregulated in several cancers, including liver hepatocellular
rcinoma, pancreatic, colon, and rectum adenocarcinomas, as well
lung adeno- and squamous cell carcinomas (Figure 7A, Table S1).
DX4 was significantly upregulated in the majority of cancers,
cluding uterine, bladder, head and neck, and kidney carcinomas,
d colon, rectum, lung, stomach adenocarcinomas, and significantly
wnregulated in liver and cholangiocarcinomas (Figure 7B). Of
terest, cancers that commonly metastasize to bone (i.e., breast,
ostate, lung, and renal cancers [1]) demonstrated significantly
gher levels of PRDX4 and, except for lung cancers, LCP1. Since our
vivo data suggested that L-plastin and PRDX4 have cooperativeles in bone metastasis (Figure 6), we examined the relationship
tween changes in LCP1 and PRDX4 expression in cancer
igure 7C). Cancer types in which L-plastin was upregulated were
nsistently characterized by a positive correlation between changes in
-plastin and PRDX4 (Figure 7C, red). In contrast, in cancer types in
hich LCP1 was downregulated, changes in LCP1 and PRDX4 were
gatively correlated (Figure 7C, blue). These data support that
P1 and PRDX4 are significantly upregulated in invasive breast
rcinoma and prostate adenocarcinoma, as well as other cancers that
mmonly metastasize to bone, with changes in PRDX4 being more
onounced than those observed in LCP1.iscussion
this study, we demonstrated that the cytosolic protein L-plastin is
leased from breast cancer cells with exosomes. Extracellular L-
astin stimulated osteoclast formation from late osteoclast precursors
the absence of RANKL. The osteoclastogenic effect of L-plastin
































































Figure 5. Generation of L-plastin and PRDX4 targeting shRNA clones. (A-D) MDA-MB-231 cells (231) were transfected with shRNA
targeting L-plastin (shL), peroxiredoxin-4 (shP), a combination of both L-plastin and PRDX4 (shLP), or an empty vector (Luc), and stable
clones were generated. Expression of L-plastin and PRDX4 in cell lysates (CL, A, B) and conditioned medium (CM, C, D) was assessed by
immunoblotting. Calnexin and Ponceau stains were used as loading controls for CL and CM, respectively. Shown are representative
immunoblots (A, C) and their quantification relative to loading control (B, D). Data are means ± SEM, N = 3 independent experiments for
L-plastin and N = 1 for PRDX4.
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ediated action of L-plastin. Using an experimental bone metastasis
odel, we demonstrated that L-plastin, together with PRDX4 which
e described previously [13], mediated breast-cancer induced
teolysis. We validated the relevance of L-plastin and PRDX4 in
man cancer biology by demonstrating that expression of LCP1 and
RDX4 was significantly increased in carcinoma samples from
tients across different cancer types, including primary invasive
east carcinoma and primary prostate adenocarcinoma.
We have now reported that two proteins with established cytosolic
nction, L-plastin (current manuscript) and PRDX4 [13], are
tively released from breast cancer cells and participate in the
tercellular communications. While PRDX4 was previously shown
have a signal peptide allowing its secretion [34] and was found in
e extracellular space [35–37], L-plastin was only reported to
nction as an actin binding protein involved in motility and invasion
6,23,38,39]. To evaluate the route of L-plastin release from breast
ncer cells, we considered that the cancer secretome consists of
acromolecules released from cancer cells by all means, including
cretion, shedding, and leaking through vesicular release [40,41].
any cytosolic proteins have been shown to be present within
osomes released from cancer cells [27,42,43]. We found that
osomes were important for breast cancer–induced osteoclast
rmation, as inhibition of exosomal release significantly reduced the
teoclastogenic potential of breast cancer–derived CM. We purified
osomes from the media conditioned by breast cancer cells and have
monstrated that L-plastin was present within the exosomal fraction,
hile PRDX4 was not. Detectable levels of L-plastin were also found in
osome-depleted CM, suggesting either the presence of an additional
ute of L-plastin release or L-plastin spillage from exosomes. In this
gard, exosomes have been demonstrated to communicate with the
rget cells through several pathways, including i) interaction of ligand
esent on the outer surface of exosomal membrane with a cell surfaceceptor; ii) release of soluble ligands through proteolytic cleavage of
osomal membrane; or iii) release of exosomal content into the
toplasm after uptake by target cells [44]. Our data demonstrate that in
dition to the established prometastatic function of intracellular L-
astin known to enhance cancer invasiveness [23,45], extracellular L-
astin contributes to cancer metastasis to bone by promoting a
vorable osteolytic microenvironment.
The establishment of osteolytic bone metastases requires the action
bone-resorbing osteoclasts [46,47]. RANKL is a key osteoclasto-
nic cytokine produced by bone-forming osteoblasts. Breast cancer
lls are known to stimulate osteoblastic expression of RANKL, which
turn stimulates osteoclast formation [48–50]. We have previously
termined that cancer cells also release factors that can serve as a
bstitute for RANKL and directly induce osteoclast formation from
ecursors deprived of RANKL after an initial period of RANKL-
ediated priming [10–12]. We have found that breast cancer cells
cking L-plastin are ineffective in inducing osteoclast formation and
at addition of recombinant L-plastin to RANKL-primed osteoclast
ecursors is sufficient to stimulate osteoclastogenesis. Moreover, we
monstrated that similar to breast cancer–derived factors, recombi-
nt L-plastin induced calcium oscillations and NFATc1 nuclear
anslocation. This signaling signature is consistent with the function
co-stimulatory immunoglobulin-like receptors previously reported
be important for osteoclastogenesis, including osteoclast-associated
ceptor (OSCAR), triggering receptor expressed in myeloid cells 2
REM2), signal-regulatory protein β1 (SIRPβ1), and paired
munoglobulin-like receptor A (PIRA) [8,51]. Our data suggest that
creted L-plastin is a novel osteoclast regulator potentially acting through
e of the co-stimulatory immunoglobulin-like receptors to augment and
rtially substitute for RANKL in promoting osteoclastogenesis.
To confirm the relevance of L-plastin for bone metastasis in vivo,
e used the experimental breast cancer bone metastasis model in











Figure 6.Double knockdown of L-plastin and PRDX4 significantly attenuates osteolysis in vivo. Six-week-old female nude CD-1 mice were
injected in the left tibiae with PBS (sham), 10,000 parental MDA-MB-231 cells, or MDA-MB-231 cells transfected with empty vector (Luc),
L-plastin (shL), peroxiredoxin-4 (shP), or both L-plastin and PRDX4 (shLP). Data from MDA-MB-231 parental and Luc groups were not
significantly different and were pooled as a single cancer group (can) for further analysis. Two weeks postsurgery, the mice were
euthanized, and hind limbs were collected for histology and μCT. (A-C) Histological evaluation. (A) Representative images of upper tibial
metaphyseal region stained for TRAP; 100-μm scale bar applies to all images. (B) The bone volume per tissue volume (BV/TV). (C) Number
of osteoclasts per bone perimeter (# OC/μm). Data are means ± SEM, N = 4-11 mice/group, *P b .05 assessed by ANOVA followed by
post hoc Bonferroni test. (D-G) μCT analysis. D) Representative 3D μCT reconstructions of the trabecular bone in the proximal tibia of mice
that were sham-operated, or injected with parental MDA-MB-231 cells (cancer) or with MDA-MB-231 cells lacking L-plastin and PRDX4
(shLP). (E) Bone volume per tissue volume (BV/TV). (F) Trabecular number (Tb.N). (G) Bone mineral density. Data are means ± SEM, N =
3-7 mice per group, *P b .05, **P b .01 compared to sham, #P b .05 compared to cancer, assessed by ANOVA and then Bonferroni test.
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e found that L-plastin–deficient MDA-MB-231 cells exhibited a
duced capacity to stimulate osteolysis in vivo. Similarly, PRDX4-
ficiency resulted in a moderate reduction in cancer-induced
teolysis in this model. Previously, we examined the role ofDX4 in prostate cancer bone metastasis using a model of tibial
jection of PRDX4-deficient human PC3 cells in CD-1 mice and
monstrated significant but partial inhibition of osteolysis [13].
portantly, MDA-MB-231 cells deficient in both L-plastin and
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d PRDX4. This model specifically targets the stage of direct
teractions between the invading cancer cells and resident bone cells
ther than the processes of selective homing, suggesting that the
duction in osteoclastogenic capacity of L-plastin- and PRDX4-
ficient breast cancer cells—rather than changes in motility or
ming—likely underlies the reduced osteolysis observed in vivo.
To examine the translational relevance of L-plastin and PRDX4,
e used the publicly available data sets to examine differential gene
pression in normal and tumor tissues of cancer patients (https://
ncergenome.nih.gov/). We found that changes in LCP1 expression
ere cancer-type specific: LCP1 was significantly increased in invasive
east carcinoma and prostate adenocarcinoma, as well as in kidney
ll carcinomas and glioblastoma, and significantly decreased in
mors originated in lower gastrointestinal tract. PRDX4 was
gnificantly upregulated in the majority of cancer types (13 of 23)
d significantly downregulated only in 2 cancer types: cholangio and
er carcinomas. Importantly, PRDX4 was significantly upregulated















Figure 7.Differential gene expression of L-plastin (LCP1) and PRDX4
in cancer. (A, B) Standardized mean difference (SMD) ± 95% CI
between LCP1 (A) and PRDX4 (B) expression in normal tissue and
primary tumors for specified cancers. BLCA: bladder urothelial
carcinoma, BRCA: breast invasive carcinoma, CESC: cervical
squamous cell carcinoma and endocervical adenocarcinoma,
CHOL: cholangiocarcinoma, COAD: colon adenocarcinoma, ESCA:
esophageal carcinoma,GBM: glioblastomamultiforme, HNSC: head
and neck squamous cell carcinoma, KICH: kidney chromophobe,
kidney renal clear cell carcinoma, KIRP: kidney renal papillary cell
carcinoma, LIHC: liver hepatocellular carcinoma, LUAD: lung
adenocarcinoma, LUSC: lung squamous cell carcinoma, PAAD:
pancreatic adenocarcinoma, PCPG: pheochromocytoma and
paraganglioma, PRAD: prostate adenocarcinoma, READ: rectum
adenocarcinoma, SARC: sarcoma, STAD: stomach adenocarcinoma,
THCA: thyroid carcinoma, THYM: thymoma, UCEC: uterine corpus
endometrial carcinoma. Red: expression significantly higher than
normal; blue: significantly lower than normal; gray: not significantly
different from normal tissue. Horizontal shaded bands: random
effects SMD estimate ± 95% CI of overall pooled SMD across all
cancer types. Arrows: Cancer types commonly associated with bone
metastases [31]. (C) Linear regression analysis of relationship
between differential expression of LCP1 and PRDX4, grouped
by cancer types in which LCP1 was either downregulated (blue)
or upregulated (red). Filled markers: significant change in LCP1
expression,emptymarkers: nonsignificant change in LCP1expression.ne—breast, prostate, lung, and kidney [52]—while LCP1 was
regulated in all except for lung cancers. These data strongly support
e potential utility of LCP1 and PRDX4 as diagnostic markers and
erapy targets. Our data are consistent with the previous studies of
RDX4, overexpression of which was identified in many cancer
pes [53], including breast [54] and prostate [52,55]. Based on the
-plastin role in tumor cell invasiveness [17,45,56–60], it was
oposed to be used as a diagnostic marker [19,61]; prognostic
arker [62]; or a therapeutic target [60,63,64]. Our data demonstrate
at extracellular L-plastin and PRDX4 have a specific role in
imulating osteoclastogenesis and thus promoting osteolysis during
ncer metastasis to bone and suggest that information regarding the
pression of these proteins may be particularly useful in cancers with
equently bone metastasis.
Supplementary data to this article can be found online at https://
i.org/10.1016/j.tranon.2018.11.014.
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